Coruno®
Partner: Therabel
Coruno® (molsidomine) is indicated for the oral treatment of chronic angina pectoris.
Manufactured at SkyePharma’s plant in Lyon, France, it uses SkyePharma’s Geomatrix™ oral delivery technology.
Coruno® is distributed, in Belgium and Luxemburg, by Therabel Group, a privately owned Belgium based company.
For further information on Coruno®, see Therabel's web site.
Copyright 2008, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom
